BIOLINERX LTD-SPONS ADR

BLRXNASDAQ

Earnings Nov 23US Equity

$2.51▼ $0.01 (−0.40%)

After hours · at close

🔔

Track BLRX

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.4%

7d▲ 1.6%

14d▼ 1.4%

30d▼ 3.8%

ytd▼ 13.1%

1y▼ 33.9%

🏦Market Cap

$6.58B

Small Cap

📈Revenue Growth (YoY)

-95.9%

Declining

📊Gross Margin

80.5%

High

💵FCF Margin

—

⚖️P/S Ratio

10.8x

Elevated

Otter Score

Weak

Trading Snapshot

Day Range: $2.47 – $2.53
52-Week Range: $1.10 – $2.40
Volume: $1.67B
Avg Volume: $1.29B
Shares Outstanding: 2.62B
Next Earnings: Oct 30, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $299,048
P/E Ratio: —
P/S Ratio: 10.8x
EPS (TTM): $-0.00
Dividend Yield: —
Dilution (1yr): +118.0%

Why Investors Own BLRX

✓High-growth profile — revenue up +44.9% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIOLINERX LTD-SPONS ADR

BLRX

Financial Trends

Revenue

$1M▼ −95.9% YoY

Gross Margin

36.2%▼ −46.8% YoY

Operating Income

−$10M▼ −49.2% YoY

Free Cash Flow

−$8M▼ −81.4% YoY

Shares Outstanding

4.4M▲ +118.0% YoY

Net Cash

−$7M▼ −$2M YoY

StockOtter · stockotter.space

About BIOLINERX LTD-SPONS ADR

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.

🦦